An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy

European Heart Journal

Volumn 23, Issue 14, 2002, Pages 1087-1092

  White, H L ^a   Maqbool, A ^a   McMahon, A D ^b   Yates, L ^a   Ball, S G ^a   Hall, A S ^a   Balmforth, A J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Beta 1 adrenergic receptor; Myocardial infarction; Polymorphism

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; DNA FRAGMENT; NITRATE; PRAVASTATIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEMODYNAMICS; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

ADULT; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1; SENSITIVITY AND SPECIFICITY;

EID: 0036629703     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3037     Document Type: Article

References (28)

1. Cruickshank JM. β-blockers: primary and secondary prevention. J Cardiovasc Pharmacol 1992; 20 (Suppl 1): S55-S69.
2. Brodde O, Michael MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 651-89.
3. Mason DA, Moore JD, Green SA et al. A gain of function polymorphism in a G-protein coupling domain of the human beta 1 adrenergic receptor. J Biol Chem 1999; 274: 12670-4.
4. Cody RJ. The sympathetic nervous system and the reninangiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997; 80: 9J-14J.
5. Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94.
6. Coehlo R, Ramos E, Prata J et al. Acute myocardial infarction: psychosocial and cardiovascular risk factors in men. J Cardiovasc Risk 1999; 6: 157-62.
7. Petterson K, Bejne B, Bjork H et al. Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via β1-adrenoceptor activation. Circ Res 1990; 67: 1027-34.
8. Shah PK. Plaque disruption and coronary thrombosis: New insight into pathogenesis and prevention. Clin Cardiol 1997; 20 (11 Suppl 2): II-38-44.
9. Johnstone MT, Mittleman M, Tofler G et al. The pathophysiology of the onset of morning cardiovascular events. Am J Hypertens 1996; 9: 22S-28S.
10. Tofler GH, Stone PH, Maclure M et al. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 1990; 66: 22-7.
11. Wikstrand J, Berglund G, Tuomilehto J. Beta blockade in the primary prevention of coronary artery disease in hypertensive patients. Review of present evidence. Circulation 1991; 84 (Suppl 6): V193-200.
12. Shepherd J, Cobbe SM, Ford I et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-7.
13. Maqbool A, Hall AS. Ball SG et al. Common polymorphisms of the beta 1-adrenoceptor: identification and rapid screening assay. Lancet 1999; 353: 897.
14. O'Shaughessy KM, Fu B, Dickerson C et al. The gain of function G389R variant of the β1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects. Clin Sci 2000; 99: 233-8.
15. Buscher R, Belger H, Eilmes KJ et al. In-vivo studies do not support a major functional role for the Gly389Arg β-adrenoceptor polymorphism in humans. Pharmacogenetics 2001; 11: 199-205.
16. Xie H-G, Dishy V, Sofowora G et al. Arg389Gly β1- adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001; 11: 191-7.
17. Haass M, Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 1997; 10: 657-65.
18. Tuomilehto J, Wikstrand J, Olsson G et al. Decreased coronary heart disease in hypertensive smokers: Mortality results from the MAPHY study. Hypertension 1989; 13: 773-80.
19. Rathz DA, Liggett SB. Hierarchy of genotype and desensitisation permutations on β1-adrenergic receptor signalling (Abstr). Circulation 2000; 102 (Suppl 2): II-102-485.
20. Yu S-M, Tsai S-Y, Guh J-H et al. Mechanism of catecholamine-induced proliferation of vascular smooth muscle cells. Circulation 1996; 94: 547-54.
21. Anfossi G, Travoti M. Role of catecholamines in platelet function: Pathophysiological significance. Eur J Clin Invest 1996; 26: 353-70.
22. Izeboud CA, Mocking JA, Monshouwer M et al. Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J Rec Sig Transduct Res 1999; 19: 191-202.
23. Small KM, Forbes SL, Rahman FF et al. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2c-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000; 275: 23059-64.
24. McGraw DW, Liggett SB. Coding block and 5 leader cistron polymorphisms of the beta2-adrenergic receptor. Clin Exp Allergy 1999; 29 (Suppl 4): 43-5.
25. British Heart Foundation. Coronary Heart Disease Statistics 1998.
26. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69.
27. Borjesson M, Magnusson Y, Hjalmarson A et al. A novel polymorphism in the gene coding for the beta 1-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21: 1853-8.
28. Tesson F, Charron P, Peuchmaurd M et al., for the CARDIGENE Group. Characterisation of a unique genetic variant in the β1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol 1999; 31: 1025-32.